Press-release for stocks for snynf

symbols : Snynf crawled time : 14:20

save search

BioSpace FDA Decision Tracker 2023: Octapharma, Tarsus, Verrica and Daiichi Sankyo
Published: 2023-07-28 (Crawled : 14:20) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K

Health Technology

| -16.14% | O: 0.47% H: 0.74% C: 0.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -12.12% | O: -3.09% H: 0.0% C: 0.0%
fda

Biopharma Lawsuit Tracker 2023: U.S. Chamber, Pfizer and BioNTech
Published: 2023-07-14 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -10.4% | O: 0.36% H: 0.0% C: 0.0%
biopharma

Apogee Files for IPO with Promising Preclinical Immuno Asset
Published: 2023-06-23 (Crawled : 14:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -13.17% | O: -2.99% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -11.71% | O: 0.74% H: 0.0% C: 0.0%
preclinical

Sona Nanotech Elects New Board Chair and is Awarded Patent
Published: 2023-05-18 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -12.6% | O: 0.16% H: 0.0% C: 0.0%
patent

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Dise...
Published: 2023-05-17 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.24% | O: -0.73% H: 0.0% C: 0.0%
genetic

Pharma, PBMs Blame Each Other Under Intense Scrutiny from Sanders’ Health Com...
Published: 2023-05-11 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.01% | O: -0.28% H: 0.0% C: 0.0%
health

FDA Approves Fabry Disease Treatment from Chiesi, Protalix
Published: 2023-05-10 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -14.54% | O: -1.75% H: 0.0% C: 0.0%
fda disease treatment

Regeneron Diversifies Portfolio as Eylea Revenue Takes a Hit
Published: 2023-05-05 (Crawled : 14:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -12.33% | O: 2.74% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.84% | O: 0.81% H: 0.0% C: 0.0%
eylea

DUPIXENT (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis
Published: 2023-05-04 (Crawled : 14:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -12.5% | O: 1.56% H: 0.0% C: 0.0%
approved dupixent treatment canada

ServiceCore Expands Roll-off Capabilities with Acquisition of Docket – Benzinga
Published: 2023-05-01 (Crawled : 14:20) - spacfeed.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -11.88% | O: 4.08% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.75% | O: -1.21% H: 0.0% C: 0.0%
acquisition

Atlas Announces Closing of Acquisition of GreenSeal, Increasing Export Capacity and Strengthening its Integrated Value Chain – Marketscreener.com
Published: 2023-05-01 (Crawled : 14:20) - spacfeed.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -11.88% | O: 4.08% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.75% | O: -1.21% H: 0.0% C: 0.0%
capacity acquisition

Bundle of Joy
Published: 2023-05-01 (Crawled : 14:20) - spacfeed.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -11.88% | O: 4.08% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.75% | O: -1.21% H: 0.0% C: 0.0%

Libtayo (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
Published: 2023-05-01 (Crawled : 14:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -11.88% | O: 4.08% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.75% | O: -1.21% H: 0.0% C: 0.0%
lung approved cancer cell treatment libtayo canada

The Global ELISA Market to Showcases Growth at a Significant CAGR of ~6% by 2027 | DelveInsight
Published: 2023-04-06 (Crawled : 14:20) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -14.32% | O: 1.36% H: 2.91% C: 2.91%
CRL | News | $239.43 -0.29% -5.0% 710K

Commercial Services

| 22.68% | O: -0.08% H: 0.55% C: 0.52%
ABBV | News | $167.8 -1.03% -0.06% 4.1M

Health Technology

| 5.44% | O: 0.0% H: 0.86% C: 0.47%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -14.77% | O: 1.13% H: 0.0% C: 0.0%
EXAS | $63.24 -0.46% -0.46% 1.2M

Health Technology

| -1.4% | O: -0.82% H: 3.93% C: 3.85%
global growth market

Thinking about trading options or stock in Regeneron Pharmaceuticals, NetEase, Netflix, Advanced Micro Devices, or Novo Nordisk?
Published: 2023-03-23 (Crawled : 14:20) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -3.5% | O: 5.54% H: 0.96% C: 0.96%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -3.61% | O: 6.53% H: 0.56% C: -0.54%

Dupixent Clears Phase III in Bid to Become First Biologic for COPD
Published: 2023-03-23 (Crawled : 14:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology